Drugs / Diosmin
Diosmin
Trials 18
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04452799 | Jul → Oct 2020 | COVID-19 | Tanta University | Unknown | No outcome recorded |
| Phase 14 trials · 1 met primary | ||||||
| Phase 1 | NCT07674446 | Jun → Aug 2026 overdue | — | Keri Pharma Hungary Kft | Recruiting | No outcome recorded |
| Phase 1 | NCT06125002 | Jan → Mar 2024 | — | Londrina State University | Unknown | No outcome recorded |
| Phase 1 | NCT05736224 | May → Sep 2023 | skin cancer | Yale University | Completed | Met primary |
| Phase 1 | NCT05158192 | Nov → Dec 2021 | — | Laboratorios Andromaco S.A. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06546111 | Oct 2024 → Oct 2025 overdue | Helicobacter pylori infectious disease | Sadat City University | Recruiting | No outcome recorded |
| Phase 36 trials | ||||||
| Phase 3 | NCT05942547 | Jul → Oct 2023 | metabolic dysfunction-associated steatohepatitis | Tanta University | Unknown | No outcome recorded |
| Phase 3 | NCT05626166 | Dec 2022 → Nov 2023 | ulcerative colitis | Tanta University | Unknown | No outcome recorded |
| Phase 3 | NCT05243706 | Mar 2022 → Sep 2023 | poisoning | Ain Shams University | Unknown | No outcome recorded |
| Phase 3 | NCT01532882 | Jan 2012 → Mar 2013 | chronic venous insufficiency | Laboratoire Innotech International | Completed | No outcome recorded |
| Phase 3 | NCT01321619 | Jul → Dec 2011 | chronic venous insufficiency, hemorrhoid | Vidfarma Indústria de Medicamentos Ltda. | Unknown | No outcome recorded |
| Phase 3 | NCT01110512 | Oct → Dec 2010 | chronic venous insufficiency | Azidus Brasil | Unknown | No outcome recorded |
| Phase 45 trials · 1 met primary | ||||||
| Phase 4 | NCT07598214 | Feb 2025 → Nov 2026 expected | cancer, familial, with in vitro Radioresistance | Beni-Suef University | Recruiting | No outcome recorded |
| Phase 4 | NCT06579482 | Nov 2024 → May 2025 | chronic venous insufficiency | Fundação Educacional Serra dos Órgãos | Completed | No outcome recorded |
| Phase 4 | NCT07588828 | Oct 2024 → Feb 2026 | female breast carcinoma | Ittefaq Hospital trust | Completed | No outcome recorded |
| Phase 4 | NCT03413618 | Dec 2017 → Jul 2019 | post-thrombotic syndrome, venous thromboembolism | Pirogov Russian National Research Medical University | Completed | Met primary |
| Phase 4 | NCT03471910 | Jun 2017 → Mar 2018 | venous insufficiency | Fundação Educacional Serra dos Órgãos | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06256575 | May 2025 → Jul 2027 expected | chronic ulcer of skin, systemic sclerosis | Primus Pharmaceuticals | Recruiting | No outcome recorded |
| Comparator or background therapy11 trials | ||||||
| Phase 1/2 | NCT02616731 Comparator | Sep 2015 → Jan 2016 | menstrual disorder | Ain Shams University | Unknown | No outcome recorded |
| Phase 2/3 | NCT02134249 Comparator | Apr 2014 → Sep 2015 | infertility disorder | Benha University | Completed | No outcome recorded |
| Phase 3 | NCT06811220 Comparator | Jan → Dec 2025 overdue | breast cancer | Alexandria University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06584799 Comparator | Dec 2024 → Jan 2025 overdue | pelvic congestion syndrome | Pirogov Russian National Research Medical University | Recruiting | No outcome recorded |
| Phase 3 | NCT05756179 Comparator | Jul 2023 → Sep 2025 overdue | rheumatoid arthritis | Alexandria University | Recruiting | No outcome recorded |
| Phase 3 | NCT05670457 Comparator | Jun 2022 → Jun 2024 | peptic ulcer disease | Tanta University | Unknown | No outcome recorded |
| Phase 3 | NCT07369635 Comparator | Jul → Sep 2020 | internal hemorrhoid | Hanoi Medical University | Completed | No outcome recorded |
| Phase 3 | NCT01477281 Comparator | Feb → Jul 2012 | chronic venous insufficiency | Laboratório Teuto Brasileiro S/A | Unknown | No outcome recorded |
| Phase 4 | NCT02782455 Comparator | Dec 2016 → Nov 2018 | hemorrhoid | Services Hospital, Lahore | Completed | No outcome recorded |
| — | NCT06333691 Comparator | Oct 2022 → Feb 2024 | ovarian hyperstimulation syndrome | Minia University | Completed | No outcome recorded |
| — | NCT04933591 Comparator | Sep 2020 → Aug 2021 | varicose disease | Pirogov Russian National Research Medical University | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 30 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Diosmin | “Patients will receive standard triple therapy (Omeprazole 20 mg cap PO BID + Clarithromycin 500 mg tab PO BID + Amoxicillin 1000 mg PO BID) and Diosmin/Hesperidin (Daflon)...” NCT06546111 ↗25“The sunscreen contains bioadhesive nanoparticles (BNP) encapsulating avobenzone and octocrylene plus the non-toxic natural products diosmin, ferulic acid, cytisine and...” NCT05736224 ↗ “diosmin , 2 tablets (500mg) t.d.s for 2 weeks in addition to cabergoline 1 tablet 0.5 mg/day orally for 8 days starting at the day of hCG injection” NCT06333691 ↗ “Diosmin 450mg and Hesperidin 50mg Tablets in Chronic Venous Insufficiency After 3 Months of Therapy” NCT06579482 ↗ “Diosmin (450 mg) + hesperidin (50 mg)” NCT01110512 ↗ “Active substance: Diosmin 1000 mg.” NCT07674446 ↗ |
| Known as | Daflon | “Control Group: Participants receiving Daflon (Diosmin).” NCT07369635 ↗ |
| Known as | Diosmin/Hesperidin (90/10) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05158192 ↗ |
| Known as | DIOVENOR | “The aim of this project led by Dr. Guex is to evaluate the efficacy and safety of diosmin 600 mg - DIOVENOR® on the painful symptoms of CVD of the lower limbs, in a...” NCT01532882 ↗ |
| Known as | DSM | “Era evaluate the effects of supplementation with the flavonoid diosmin (DSM) on athletic performance and DOMS-related symptoms in the pre-season of a futsal team from the...” PMID 40818103 ↗ Aug 2025 |
| Modality | Small molecule | “flavonoids combination (diosmin and hesperidin)” NCT05756179 ↗ |
| Route | Oral | “Administered one tablet two times daily (oral)” NCT01321619 ↗ |